Home/Filings/4/0001062993-25-001237
4//SEC Filing

Kelderman Kim 4

Accession 0001062993-25-001237

CIK 0000842023other

Filed

Jan 28, 7:00 PM ET

Accepted

Jan 29, 4:35 PM ET

Size

33.1 KB

Accession

0001062993-25-001237

Insider Transaction Report

Form 4
Period: 2025-01-27
Kelderman Kim
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-27$37.70/sh+13,392$504,87852,396 total
  • Sale

    Common Stock

    2025-01-27$77.19/sh11,731$905,53340,665 total
  • Sale

    Common Stock

    2025-01-27$77.95/sh1,661$129,48039,004 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-01-2713,3920 total
    Exercise: $37.70Exp: 2025-05-01Common Stock (13,392 underlying)
Holdings
  • Performance Stock Options (Right to Buy)

    Exercise: $68.54Exp: 2031-02-01Common Stock (25,945 underlying)
    25,945
  • Stock Options (Right to Buy)

    Exercise: $68.54Exp: 2031-02-01Common Stock (51,890 underlying)
    51,890
  • Performance Restricted Stock Units

    Common Stock (51,261 underlying)
    51,261
  • Stock Options (Right to Buy)

    Exercise: $74.91Exp: 2034-08-15Common Stock (69,061 underlying)
    69,061
  • Performance Restricted Stock Units

    Common Stock (8,873 underlying)
    8,873
  • Stock Option (Right to Buy)

    Exercise: $44.33Exp: 2025-08-08Common Stock (84,308 underlying)
    84,308
  • Stock Option (Right to Buy)

    Exercise: $66.97Exp: 2027-08-05Common Stock (115,724 underlying)
    115,724
  • Stock Option (Right to Buy)

    Exercise: $120.46Exp: 2028-08-06Common Stock (25,944 underlying)
    25,944
  • Performance Stock Options (Right to Buy)

    Exercise: $94.52Exp: 2029-08-15Common Stock (21,704 underlying)
    21,704
  • Stock Options (Right to Buy)

    Exercise: $94.52Exp: 2029-08-15Common Stock (28,940 underlying)
    28,940
  • Restricted Stock Units

    Common Stock (25,630 underlying)
    25,630
  • Stock Option (Right to Buy)

    Exercise: $47.60Exp: 2026-08-07Common Stock (109,536 underlying)
    109,536
  • Performance Restricted Stock Units

    Common Stock (6,984 underlying)
    6,984
  • Performance Stock Options (Right to Buy)

    Exercise: $84.61Exp: 2030-08-15Common Stock (23,881 underlying)
    23,881
  • Stock Options (Right to Buy)

    Exercise: $84.61Exp: 2030-08-15Common Stock (29,391 underlying)
    29,391
  • Stock Options (Right to Buy)

    Exercise: $52.83Exp: 2030-11-01Common Stock (38,252 underlying)
    38,252
  • Performance Restricted Stock Units

    Common Stock (9,423 underlying)
    9,423
Footnotes (14)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F10]Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
  • [F11]Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
  • [F12]Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F13]8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
  • [F14]Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.69 to $78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]Fully exercisable.
  • [F4]Options to purchase 6,484 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 6,488 shares vest on each of 8/6/2024 and 8/6/2025.
  • [F5]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F6]Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F7]Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.
  • [F8]Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F9]Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.

Issuer

BIO-TECHNE Corp

CIK 0000842023

Entity typeother

Related Parties

1
  • filerCIK 0001739054

Filing Metadata

Form type
4
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 4:35 PM ET
Size
33.1 KB